Patents by Inventor Daniel Dairaghi

Daniel Dairaghi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heteroaryl sulfonamides and CCR2
    Publication number: 20070037794
    Abstract: Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.
    Type: Application
    Filed: July 14, 2006
    Publication date: February 15, 2007
    Inventors: Solomon Ungashe, Zheng Wei, Arindrajit Basak, Trevor Charvat, Wei Chen, Jeff Jin, Jimmie Moore, Yibin Zeng, Sreenivas Punna, Daniel Dairaghi, Derek Hansen, Andrew Pennell, John Wright
  • Heteroaryl sulfonamides and CCR2
    Publication number: 20060173019
    Abstract: Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.
    Type: Application
    Filed: January 13, 2006
    Publication date: August 3, 2006
    Inventors: Solomon Ungashe, Zheng Wei, Arindrajit Basak, Trevor Charvat, Jeff Jin, Jimmie Moore, Yibin Zang, Sreenivas Punna, Daniel Dairaghi, Derek Hansen, Andrew Pennell, John Wright
  • Mammalian chemokine reagents
    Publication number: 20060153802
    Abstract: A novel CC chemokine which is from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokine. A chemokine receptor is also provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Application
    Filed: March 20, 2006
    Publication date: July 13, 2006
    Inventors: Daniel Dairaghi, Takahiko Hara, Atsushi Miyajima, Thomas Schall, Wei Wang, Akihiko Yoshimura
  • Substituted piperazines
    Publication number: 20060106218
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: December 8, 2004
    Publication date: May 18, 2006
    Applicant: ChemoCentryx, Inc.
    Inventors: Andrew Pennell, James Aggen, J.J. Wright, Subhabrata Sen, Brian McMaster, Daniel Dairaghi, Wei Chen, Penglie Zhang
  • Bicyclic and bridged nitrogen heterocycles
    Publication number: 20060074121
    Abstract: Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.
    Type: Application
    Filed: September 1, 2005
    Publication date: April 6, 2006
    Applicant: ChemoCentryx, Inc.
    Inventors: Wei Chen, Penglie Zhang, James Aggen, Daniel Dairaghi, Andrew Pennell, Subhabrata Sen, J.J. Wright
  • Compounds and methods for modulating CXCR3 function
    Publication number: 20060063763
    Abstract: Compounds and compositions are provided that bind to the CXCR3 chemokine receptor and which are useful for treating diseases associated with CXCR3 activity, such as multiple sclerosis.
    Type: Application
    Filed: September 8, 2005
    Publication date: March 23, 2006
    Inventors: Thomas Schall, Daniel Dairaghi, Brian McMaster
  • Substituted piperazines
    Publication number: 20050256130
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: November 1, 2004
    Publication date: November 17, 2005
    Applicant: ChemoCentryx, Inc.
    Inventors: Andrew Pennell, James Aggen, J.J. Wright, Subhabrata Sen, Brian McMaster, Daniel Dairaghi, Wei Chen, Penglie Zhang
  • Method for identifying a modulator of the binding of CCX CKR polypeptide to a chemokine
    Publication number: 20050239130
    Abstract: The invention provides polypeptides and polynucleotides encoding a novel chemokine receptor, CCX CKR. The invention further provides reagents and methods for identifying agents that modulate the activity or expression of the receptors, as well as methods for detecting receptor expression.
    Type: Application
    Filed: June 28, 2005
    Publication date: October 27, 2005
    Applicant: ChemoCentryx, Inc.
    Inventors: Jennifa Gosling, Daniel Dairaghi, Zhenhua Miao, Thomas Schall
  • Bicyclic and bridged nitrogen heterocycles
    Publication number: 20050234034
    Abstract: Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.
    Type: Application
    Filed: March 2, 2005
    Publication date: October 20, 2005
    Applicant: ChemoCentryx, Inc.
    Inventors: Andrew Pennell, James Aggen, J.J. Wright, Subhabrata Sen, Wei Chen, Daniel Dairaghi, Penglie Zhang